Knee pain chart review

Study record

Population

17 patients identified; 16 contacted, aged 19–77 years (9 women, 7 men).

Read source · Full-text reportMethods — Patients, page 9

Formulation

Compounded preparations: BPC-157 alone (12 patients) or with TB4 (4 patients). Sodium phosphate buffer and benzyl alcohol were reported.

Read source · Full-text reportProcedure, page 9; Results, page 10

Route

Intra-articular knee injection

Read source · Full-text reportProcedure, pages 9–10

Dose & frequency

Reported intra-articular doses: BPC-157 alone 4 mg; combination subgroup BPC-157 2–4 mg with TB4 3–6 mg. Two patients received repeat BPC-157 injections after reinjury. This uncontrolled report does not establish a dose or cycle.

Read source · Full-text reportProcedure, pages 9–10; Results and Tables 1–2, page 10

Study design

Single-clinic retrospective chart review and telephone survey; no randomized comparator. Combination treatment preceded use of BPC-157 alone.

Read source · Full-text reportStudy design and Inclusion criteria, page 9; follow-up, page 10

Duration

Variable follow-up, generally 6–12 months after injection. Follow-up and reported relief duration are not continuous dosing schedules.

Read source · Full-text reportAbstract Methods, page 8; follow-up and Tables 4–5, page 10

Reported findings

Pain improvement reported by 11/12 receiving BPC-157 alone and 3/4 receiving the combination.

Read source · Full-text reportResults and Tables 1–2, page 10

Adverse events

Authors reported no adverse events, based on retrospective follow-up. This small sample and ascertainment method cannot establish safety.

Read source · Full-text reportFollow-up questions, page 10; Discussion, page 12

Monitoring

Telephone follow-up asked about pain, function, and adverse events. No objective improvement testing was performed.

Read source · Full-text reportRetrospective chart review and follow-up questions, page 10